Gaucher Disease Drugs Market - Top Companies and Manufacturers

Companies Dominating the Gaucher Disease Drugs Landscape

The global gaucher disease drugs market is poised for robust growth during the forecast period. Companies in the sector are investing in acquisitions for better distribution of drugs and investments in research and clinical trials to improve the efficacy of treatment.

Here are some key players in the market:

Pfizer Inc.

Company Overview

Business Strategy

Key Product Offerings

Financial Performance

Key Performance Indicators

Risk Analysis

Recent Development

Regional Presence

SWOT Analysis

CANbridge Pharmaceuticals Inc.
Johnson & Johnson Private Ltd.
AVROBIO Inc.
Amicus Therapeutics Inc.
Novartis AG
Sanofi
Amerigen Pharmaceuticals Ltd.
Dipharma S.A

Browse Key Market Insights with Data Illustration:

Gaucher Disease Drugs Market Size & Share, Growth Report 2037

In the News

In September 2024, CANbridge Pharmaceuticals Inc., reported that CAN103 (velaglucerase-beta), a recombinant human glucocerebrosidase ERT that is being developed to treat GD Types I and III, has been granted priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
In May 2024, CENTOGENE and Evotec announced the discovery of a promising new molecule to treat gaucher disease. The new molecule has the potential to treat patients with type 2 and type 3 gaucher disease.

Frequently Asked Questions (FAQ)

The gaucher disease drugs marker registered USD 1.7 billion in 2024 and is projected to expand at a profitable CAGR of 3.3% during the forecast period, i.e., 2025-2037.

The global gaucher disease drug market registered a profitable valuation of USD 1.7 billion in 2024 and is projected to register USD 2.6 billion by 2037, expanding at a CAGR of 3.3% during the forecast period, i.e., 2025-2037.

The major players in the market are Pfizer Inc., CANbridge Pharmaceuticals Inc., Johnson & Johnson Private Ltd., AVROBIO Inc., Amicus Therapeutics Inc., Novartis AG, Sanofi, Amerigen Pharmaceuticals Ltd., and Dipharma S.A.

The enzyme replacement therapy (ERT) of the gaucher disease drugs industry registered the largest revenue share in 2024 due to increasing adoption for Gaucher disease treatment.

North America is projected to hold a dominant share of 31.2% by 2037 in the global gaucher disease drugs sector owing to a favorable regulatory ecosystem in the region supporting clinical trials and drug approvals.

Gaucher Disease Drugs Market - Top Companies and Manufacturers

Companies Dominating the Gaucher Disease Drugs Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the gaucher disease drugs market?

What is the outlook for the gaucher disease drugs market?

Who are the major players dominating the gaucher disease drugs market?

Which product segment will capture the significant market share for the gaucher disease drugs sector by 2037?

Which region will provide more business opportunities for the growth of the gaucher disease drugs market in the future?